News

Experts reveal potential unintended side effect of Ozempic – and whether we should worry

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a ...
Asianet Newsable on MSN57m

Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side

UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340 ($52.59), down from DKK 600. The new price target still implies a near 9% upside to the stock’s closing price on ...